How to Sign Up for a Retatrutide Clinical Trial

Where to Find Trials

Which Trials Are Still Enrolling

General Eligibility Criteria

Eligibility is trial-specific. The currently recruiting SYNERGY-Outcomes record requires evidence of liver disease beyond BMI alone.

Inclusion Criteria

The master protocol lists liver fat content of at least 8%, an ELF score from 9 to 10.8, and liver stiffness by VCTE from 10 to less than 20 kPa. Adults must be at least 18 years old. These are screening measures for the study team to interpret, not self-diagnosis criteria.

Exclusion Criteria

Examples in that record include other liver diseases, BMI below 25, prior decompensated liver disease, more than 11 lb of weight loss in the previous three months, HbA1c above 10%, and type 1 diabetes. The study team checks all criteria and any substudy requirements.

Other trials use different rules. A medication restriction in one TRIUMPH protocol should not be treated as a universal washout instruction.

How the Enrollment Process Works

Step 1: Search for Active Trials

Use ClinicalTrials.gov or Lilly Trial Connect to find recruiting trials near your location. Filter for "Recruiting" status.

Step 2: Review the Details

Check inclusion and exclusion criteria against your health profile. Note the study duration, visit frequency, and location requirements. Ask how long your own participation lasts, how often visits occur and whether imaging or other assessments require travel. A registry's overall study completion date is not your individual participation period.

Step 3: Contact the Trial Site

Each trial listing includes phone numbers and email addresses for study sites. Some sites have online contact forms. Your current doctor may be able to facilitate the referral.

Step 4: Screening

If you pass initial eligibility checks, the screening process includes:

• Informed consent — explanation of known and potential risks, possible benefits and study procedures
• Lab work and vital signs
• Full medical history review
• BMI verification
• Medication review
• Condition-specific assessments (e.g., knee X-rays for OA trials, eGFR for kidney trials)

Step 5: Randomization

Randomization and blinding depend on the protocol. Some studies compare retatrutide with placebo; TRIUMPH-5 compares it with tirzepatide. Ask which treatments the study uses and your assignment probabilities. In a blinded study, participants generally do not know their assigned treatment.

What to Expect During the Trial

Duration and Visits

Ask the site for the visit schedule, testing requirements, time away from work and follow-up period. These vary by protocol. Tell the team about symptoms and medication changes throughout the study.

Dose Titration

The study team supplies and manages the protocol's dosing schedule. Published trial doses are not instructions for applicants to start, stop or alter medication before screening.

The Placebo Question

A placebo-controlled study does not guarantee active treatment. Other protocols use an active comparator instead. Ask about the assigned treatments, masking, rescue treatment and any extension before consenting. Do not infer a placebo probability from another TRIUMPH trial.

What You Receive

Lilly says most studies provide investigational medicine and study visits at no cost, but costs and payments vary. Confirm the details in the consent document before joining.

What You Do NOT Receive

Enrollment does not guarantee benefit or assignment to retatrutide. It also does not establish continued access after the study. Ask specifically about any extension and the plan for care when participation ends.

You can withdraw from a trial. Discuss safe withdrawal and follow-up with the study team rather than stopping contact or medication without a plan.

Frequently Asked Questions

Sources

• Lilly Medical. (2026). What retatrutide clinical trials are being conducted in people with obesity or overweight? Link.
• Midi Health. (2026). How to Get Retatrutide with a Clinical Trial. Link.
• ClinicalTrials.gov. TRIUMPH trials: NCT05929066, NCT05931367, NCT06383390.
• Giblin, M.J., et al. (2026). Design of the TRIUMPH Phase 3 program. Diabetes, Obesity and Metabolism. PubMed.
• ClinicalTrials.gov. SYNERGY-Outcomes, TRIUMPH-7, and TRIUMPH-5. Status checked September 8, 2026.
• Lilly. Clinical trial information and informed consent.
• FDA. Payment and reimbursement to research subjects.